Focused On-demand Library for Large ribosomal subunit protein uL5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P62913

UPID:

RL11_HUMAN

Alternative names:

60S ribosomal protein L11; CLL-associated antigen KW-12

Alternative UPACC:

P62913; P25121; P39026; Q8TDH2; Q9Y674

Background:

Large ribosomal subunit protein uL5, also known as 60S ribosomal protein L11 and CLL-associated antigen KW-12, plays a pivotal role in protein synthesis. It is a crucial component of the ribosome, facilitating the synthesis of proteins by translating mRNA messages and catalyzing peptide bond formation. This protein is also integral to the maturation of rRNAs and ribosome biogenesis, linking these processes to p53/TP53 activation.

Therapeutic significance:

Given its involvement in Diamond-Blackfan anemia 7, a condition characterized by hypoplastic anemia and increased malignancy risk, understanding the role of Large ribosomal subunit protein uL5 could open doors to potential therapeutic strategies.